Large-Scale Genetic Study Identifies Novel Autism Risk Genes & Common Biological Pathways

A major new study published on March 30, 2026, in Nature Medicine reports that deleterious coding variation associated with autism spectrum disorder is shared across diverse ancestries. The findings challenge previous assumptions about the specificity of genetic risk factors and support more inclusive approaches to genomic medicine. The research highlights a universal biological basis for autism risk, suggesting that genetic screening and counseling strategies may be applicable across different populations.

The study represents a significant global collaboration involving researchers from the Icahn School of Medicine at Mount Sinai, the Broad Institute of MIT and Harvard, and numerous international institutions. The author affiliations list includes contributors from the United States, Brazil, Colombia, Peru, Mexico, Finland, Italy, Spain, Japan, and other regions. This broad geographic participation was central to the study’s ability to analyze genetic data across varied ancestral backgrounds.

According to the study metadata, the research was conceived and designed by a team including Kathryn Roeder, Bernie Devlin, Catalina Betancur, and Joseph D. Buxbaum. Joseph D. Buxbaum supervised the study, which drew on samples and data generated by a wide network of contributors. The extensive list of participating centers underscores the complexity of gathering diverse genetic data necessary to validate findings across populations.

Implications for Genomic Medicine

The results align with growing evidence that both rare and common genetic risk factors for complex disorders are shared across diverse populations. By demonstrating broad overlap in autism risk genes across ancestries, the research reinforces the universal biological underpinnings of the condition. This has direct implications for how genetic testing is implemented in clinical settings.

Historically, genomic databases have been skewed toward populations of European ancestry, which can limit the accuracy of risk prediction for individuals from other backgrounds. The confirmation that risk variants are shared suggests that insights gained from one population can inform understanding in others. This supports the development of more equitable diagnostic tools and therapeutic targets that do not exclude underrepresented groups.

Context of Autism Genetics Research

Autism spectrum disorder is a complex neurodevelopmental condition with a strong genetic component. Previous large family studies have identified genes where risk is driven by rare loss-of-function inherited variants. Research published in NPJ Genomic Medicine involving 116 autism families identified rare potentially damaging de novo sequence variants and copy number variants. That work highlighted the role of both de novo and inherited variants in neurodevelopmental disorders.

Other large-scale efforts, such as the SPARK research cohort, have analyzed the DNA of nearly 43,000 people with autism. Findings from the SPARK study, published in Nature Genetics in August 2022, identified a group of novel moderate-effect genes that tend to contribute to autism through inherited variants. While previous studies primarily identified autism genes with de novo variants that are not inherited, newer research is increasingly appreciating the role of inherited genetic contributions.

Wendy Chung, principal investigator of SPARK, noted that genetic contributions to different phenotypes vary in terms of the genes involved and when those genes are activated during brain development. The 2026 Nature Medicine study builds on this foundation by confirming that the specific coding variations linked to risk are not isolated to specific ancestral groups.

International Collaboration and Data

The 2026 study relied on a massive consortium of institutions to achieve its statistical power and diversity. Affiliations listed in the publication include the Seaver Autism Center for Research and Treatment, the Department of Psychiatry at Mount Sinai, and the Friedman Brain Institute. International partners included the Universidade de São Paulo in Brazil, the Universidad de los Andes in Colombia, and the Centro Ann Sullivan del Peru.

In the United States, participating institutions extended beyond New York to include the University of Pittsburgh School of Medicine, Kaiser Permanente Northern California, the University of California Davis MIND Institute, and the University of Miami Miller School of Medicine. European contributors included the University of Helsinki in Finland, the University of Siena in Italy, and Aarhus University in Denmark. This structure allowed the researchers to pool resources and data that would be unavailable to a single center.

The study’s methodology involved integrating de novo and inherited variants to identify mutations. The interpretation of identified variants followed established guidelines, such as those from the ACMG, to determine molecular diagnoses. The researchers noted that while current figures represent a lower limit for diagnosis rates, these numbers are expected to increase as the role of likely pathogenic variants in candidate genes is further clarified.

Future Directions in Neurodevelopmental Research

The identification of shared risk genes opens new avenues for understanding the neurobiological bases of neurodiversity across common developmental disorders. Researchers are now focusing on characterizing the allelic diversity, mode of inheritance, and phenotypic impact of these variants. As the role of candidate genes not yet fully established becomes clearer, the potential for molecular diagnosis in autism cases is expected to rise.

The findings also contribute to the broader characterization of how genetic variants influence the autism spectrum. This includes individuals with profound autism who often have cognitive differences or epilepsy, as well as individuals who are talented and exceptional in specific areas. Understanding the shared genetic architecture helps frame autism not as a collection of disjointed conditions, but as a spectrum with common biological roots that manifest differently across individuals.

Continued research into these shared genetic factors aims to refine risk assessment and support the development of interventions that address the core biological mechanisms of the disorder. The collaborative model demonstrated by this study sets a precedent for future genomic research, emphasizing the necessity of diversity in study populations to ensure medical advances benefit all patients.